|
Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma (ACC) with NOTCH signaling pathway activation. |
|
Brindley Sonal Hapuarachi |
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst); Vyriad (Inst) |
Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Merck Serono (Inst); MSD (Inst); Oncolys BioPharma (Inst); Replimune (Inst); Vyriad (Inst) |
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst) |
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Replimune (Inst) |
|
|
No Relationships to Disclose |